Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 456534, 7 pages
http://dx.doi.org/10.1155/2012/456534
Research Article

Overexpression of Runt-Related Transcription Factor-2 Is Associated with Advanced Tumor Progression and Poor Prognosis in Epithelial Ovarian Cancer

1Department of Gynaecology and Obstetrics, Clinical Section, PLA General Hospital, Beijing 100853, China
2Anesthesia and Operation Center, Clinical Section, PLA General Hospital, Beijing 100853, China
3Department of Gynaecology and Obstetrics, Yantaishan Hosptial, Shandong, Yantai 264000, China
4Clinical Section, PLA General Hospital, Beijing 100853, China

Received 13 May 2012; Revised 4 August 2012; Accepted 4 August 2012

Academic Editor: Andre Van Wijnen

Copyright © 2012 Weiping Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aim. To investigate clinical significance of runt-related transcription factor (RUNX)-2 in epithelial ovarian cancer (EOC). Methods. RUNX2 protein expression and its subcellular localization were detected by immunohistochemistry in 116 patients with EOC. Results. RUNX2 protein was predominantly expressed in cell nucleus of EOC tissues. The expression level of RUNX2 in EOC tissues was significantly higher than that in normal ovarian tissues ( 𝑃 < 0 . 0 0 1 ) . In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues ( 𝑃 = 0 . 0 0 1 ) . Moreover, EOC patients with high RUNX2 LI had significantly shorter overall ( 𝑃 < 0 . 0 0 1 ) and progression-free ( 𝑃 = 0 . 0 0 2 ) survival than those with low RUNX2 LI. Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups. Conclusions. Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients. RUNX2 might be a novel prognostic marker of EOC.